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Abstract
Introduction: Nodal metastasis is a main prognostic factor in vulvar cancer. Increased vascular endothelial growth factor C (VEGF-C) 
expression has been associated with lymph node metastasis and poor prognosis in many cancers. The aim of this retrospective study was to 
investigate VEGF-C expression pattern in the invasive edge of vulvar cancer and in sentinel lymph node metastasis, and its association with 
the stage and prognosis. Methods: Tumor and sentinel lymph node samples from 44 patients were evaluated with immunohistochemistry, 
and the results were linked with the clinicopathological data. Results: Sixty-seven percent of primary tumors and 76% of sentinel lymph 
node metastases expressed VEFG-C. Positive VEGF-C expression of the primary tumor did not predict surgical Stage or sentinel lymph 
node involvement. The risk of relapse was not significantly higher with VEGF-C expressing tumors than with VEGF-C negative tumors (RR 
2.55, 95% CI 0.66-9.90, p = 0.18). The risk of groin recurrence was significantly lower with VEGF-C positive than negative tumors (RR 0.36, 
95% CI 0.16-0.79, p = 0.01). Survival was similar in both groups. No non-sentinel lymph node metastases were found in case of negative 
VEGF-C expression in the sentinel lymph node metastasis, whereas with positive VEGF-C expression they were found in 5/13 (38%) of cases. 
Conclusions: Tumoral VEGF-C expression was not associated with higher surgical Stage or poorer prognosis in vulvar cancer. However, 
absence of its expression in sentinel lymph node metastasis might indicate a low risk for non-sentinel lymph node metastases.
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Introduction
Nodal metastatic involvement is the most important 
prognostic factor in vulvar cancer. Node-negative patients 
have a 5-year survival rate of 70 - 98% but those with positive 
nodes only 12 - 41% [1]. Size of the primary tumor, presence 
of lymphovascular invasion and the depth of invasion are 
known to increase the risk for nodal metastasis [2–4], as 
well as the central location of the primary tumor [5]. Biologic 
prognostic variables are not as well known. Increased 
tumor angiogenesis and altered vessel characteristics are 
suggested to lead into a shorter disease-free survival [6]. 
Expression levels of matrix metalloproteinase-2 expression 
higher than 50% are also an indicator of a lower five-
year survival rate [7]. Over-expression of tissue matrix 
metalloproteinases, transmembrane protein CD44 and its 
isoforms, thrombospondin-1, vascular endothelial growth 
factor (VEGF) and some G2/M pathway regulators, as well 
as, loss of metastasis suppressor NM23-H1 gene, seem 
to promote local and metastatic growth. However, not all 
these findings correlate with clinical prognosis [1, 8].
Studies in animal models and humans have shown that 
lymphangiogenesis in a primary tumor increases nodal 
metastasis [9]. Even before the metastasis actually takes 
place, the lymph nodes draining straight from the tumor – 
so called sentinel lymph nodes (SLNs) - undergo remodelling 
processes including lymphangiogenesis, alterations in 
structure, lymphatic flow and immune cell composition, 
and increases in chemokine and cytokine production, thus 
creating a premetastatic niche [10]. Vascular endothelial 
growth factor C (VEGF-C) secreted by the primary tumor 
is the most important lymphangiogenic factor causing the 
remodelling. It alters the lymphatic vessels around the 
primary tumor, increases the lymphatic flow and causes 
expansion of lymphatic network in SLNs, all this promoting 
lymphatic spread [11].
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In many human cancers, over-expression of VEGF-C by 
primary tumor is associated with poorer prognosis. It 
correlates with shorter progression free survival (PFS), 
overall survival (OS) and lymph node metastasis in 
melanoma [12], and is a poor prognostic factor in non-
small-cell lung cancer and adenocarcinoma of the lung 
[13, 14]. High levels of VEGF-C expression in gastric cancer 
tissue imply worse overall prognosis than low VEGF-C 
levels [15]. Primary tumor VEGF-C expression has been 
reported to correlate with the possibility of lymph node 
metastasis in lung, oesophageal, prostate, thyroid and 
colorectal cancers [11].
To our knowledge, the influence of VEGF-C on the clinical 
course of vulvar cancer has not been studied, but one 
report of VEGF-C expression in 10 tissue samples has been 
published [16]. The aim of this study was to explore the 
presence of VEGF-C expression in vulvar cancer (primary 
tumor and SLN metastasis), and its influence on patients’ 
surgical Stage, risk of recurrence and prognosis.
Materials and methods
Patients and tissue samples
Tissue samples from 44 vulvar cancer patients that had 
previously undergone vulvar surgery and a SLN mapping 
before complete lymph node dissection in Tampere 
University Hospital were used for this study. Under a 
4.5-year familiarization period, a SLN mapping had been 
performed to all surgically treated vulvar cancer patients, 
and has been described elsewhere [17]. The specimens 
were obtained from the Tissue Biobank and Research 
Services FinTiB (Fimlab Laboratories Inc., Tampere, 
Finland). Forty-six tumor samples with representative 
malignant growth as well as 17 metastatic SLN samples 
were available for analysis.
The clinicopathological history and follow-up data of all 
patients were retrospectively collected from the hospital 
records. The history included the age at the time of the 
surgery, the date of the surgery, the site of the primary 
tumor, the type of surgery, the surgical Stage of the disease, 
the histopathology report, the status of the SLN (positive or 
negative for metastasis) and other regional lymph nodes, 
and whether or not other metastases were present. The 
follow-up data included also information of a potential 
adjuvant treatment and its duration, the observation date 
and location(s) of a recurrence, if any, the final date of the 
follow-up, and the date and cause of death, if it happened 
during the follow-up period. This data was combined with 
the results of the VEGF-C immunostaining for the final 
analysis.
Immunohistochemistry
The VEGF-C protein expression in vulvar tumors and SLN 
samples were evaluated by using immunohistochemistry 
(IHC). Representative samples from the invasive edges of 
the primary tumors and SLN metastases were selected for 
the study by an experienced pathologist (M.L.). 4 µm thick 
sections were cut from paraffin-embedded tissue blocks 
using a standard microtome. For IHC staining, the slides 
were then deparaffinized, rehydrated, and subsequently 
pretreated with a PT-Module (Lab Vision, Fremont, CA) at 
98°C for 15 min in 0.05 M TrisHCl buffer, pH 9.0 containing 
0.001 M EDTA. The primary VEGF-C antibody (Rabbit anti-
VEGF-C; Invitrogen, Camarillo, CA) was visualized with a 
PowerVision + polymer kit (Leica Biosystems Newcastle 
Ltd., Newcastle, UK) and diaminobenzidine as chromogen 
(DABImmPact, Vectorlabs, Burlingame, CA). The tissue 
sections were counterstained with hematoxylin (Mayer’s 
hematoxylin, Oy FFChemicals Ab, Haukipudas, Finland). 
Human colon carcinoma samples, known to have a strong 
VEGF-C expression, were used as a positive control. 
Negative controls were made by omitting the primary 
VEGF-C antibody from the procedure.
Analysis of the immunostaining
Immunostained sections were scanned with an Aperio 
Scanscope XT (Aperio Technologies, Vista, CA) and visually 
analysed on a computer screen. Two observers (R.N. and 
S.S.) assessed them, blinded to the clinicopathological data 
of the patients. In the first round, the assessments were 
performed independently and the results then pooled. 
If the assessments of two observers were contradictory, 
the staining was assessed again in consensus. In all 
tissue samples, IHC staining intensity was scored 
semiquantitatively as negative (no staining at all), weak 
(some scattered stained cells or faint more widespread 
staining), moderate (more abundant widespread staining 
or focal intensive staining) or strong (almost all cells 
intensively stained). For the statistical analysis, negative and 
weak staining were combined as “negative” and similarly, 
moderate and strong staining as “positive” staining.
Statistical analysis
The concordance between two observer’s assessments 
of the VEGF-C expression in the first evaluation round 
was assessed using Cohen’s unweighted kappa test 
[18]. Associations between VEGF-C staining and 
clinicopathological parameters were analyzed using the 
Fisher’s exact test, odds ratio and relative risk. Disease-
specific and progression free survival curves were 
calculated using Kaplan-Meier survival analysis, and 
compared using the log rank test. A p-value less than 0.05 
was considered statistically significant. SPSS Statistics for 
Windows (version 19.0 released 2010, IBM Corp., Armonk, 
NY, USA) was used in calculation of statistical analysis.
Ethical considerations
The use of archived tissue specimens for IHC was approved 
by Valvira, National Supervisory Authority for Welfare 
and Health (6746/05.01.00.06/2009). The retrospective 
collection of patient data from the hospital records was 
approved by the Ethics Committee of Pirkanmaa Hospital 
District (R09066).
Results
Patient and follow-up data
The median age of patients was 76 years (range 44-93). 
The median follow-up time was 39 months (range 0.6 - 
109 months). Tumor characteristics with Stage, adjuvant 
treatment and follow-up data are presented in Table 1.
During the follow-up, one patient died of cancer less than 
three weeks after surgery and two patients during the 
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adjuvant radiotherapy before completion of the treatment 
(7%, 3/44). Thirteen patients (30%) had a recurrence after 
the completion of the treatment, 7 in the vulva and 6 
outside the vulva. Three out of 7 patients (43%) with vulvar 
recurrence were salvaged by reoperation and were alive 
at the end of the follow-up, while all six patients with 
recurrences outside vulva died of their disease. At the end 
of the follow-up, half of the patients were still alive.
Interobserver agreement on IHC
The interobserver agreements on the VEGF-C expression in 
primary tumor and SLN samples were substantial; Cohen’s 
unweighted kappa for concordance in tumor samples was 
0.69 (95% CI 0.48-0.90) and in SLN samples 0.72 (95% CI 
0.50-1.06).
VEGF-C expression in primary tumors and SLN metastases
Of 46 primary tumor samples, only 7% (3/46) of the invasive 
edges of vulvar tumors did not express any VEGF-C. The 
expression was weak in 26% (12/46). Thus, altogether 15 
tumors (33%) were classified as VEGF-C negative (Figure 
1a). The staining was moderate or strong in 53% (25/46) 
and 13% (6/46) of the tumor edges, respectively, and a total 
of 31 (67%) tumors classified as VEGF-C positive (Figure 1b). 
There was no difference in median age of patients with 
either VEGF-C negative or VEGF-C positive tumors (75.5 
vs. 76 years, p = 1.00). The high- Grade tumors tended to 
express VEGF-C more often than the low-Grade tumors but 
the difference was not statistically significant (p = 0.36), see 
Figure 2. For one tumor, the Grade was not available.
Table 1 Data on disease and tumor characteristics in all 44 patients.
Variable Definition Number of patients (percentage of all)
FIGOa Stage I 19 (43%)
II 4 (9%)
III 20 (46%)
IV 1 (2%)
Histology and Grade of the 
primary tumor in vulva
SCCb 43 (98%)
Grade 1 22 (50%)
Grade 2 14 (32%)
Grade 3 7 (16%)
Anaplastic 
carcinoma
1 (2%)
Grade 3 1 (2%)
Sentinel node metastasis No 23 (52%)
Yes 20 (46%)
No SLN detected 1 (2%)
Postoperative adjuvant 
treatment
No adjuvant 
treament
22 (50%)
RTc 21 (48%)
Concurrent CRTd 1 (2%)
Alive at the end of the 
follow-up
Yes 22 (50%)
No 22 (50%)
Cause of death Vulvar cancer or 
related
15 (34%)
Other cause 7 (16%)
aThe International Federation of Gynecology and Obstetrics; bsquamous 
cell carcinoma; cradiation therapy; dchemoradiotherapy
Figure 1 Examples of (a) a weak and (b) a strong VEGF-C immunostaining in 
squamous cell carcinoma of the vulva (magnification x 20).
Tumoral VEGF-C expression and surgical Stage
At the time of the surgery, 17 out of 30 (57%) VEGF-C 
positive and 8 out of 14 (57%) VEGF-C negative tumors 
were advanced (> FIGO Stage I). The risk for more advanced 
surgical Stage was the same with VEGF-C positive and 
negative tumor groups (OR 0.98, 95% CI 0.27-3.53, p = 
0.98). Also, the risk of having SLN metastasis at the time 
of surgery did not significantly differ between VEGF-C 
positive or negative tumors (47%, 14/30 and 46%, 6/13, 
respectively; OR 1.02, 95% CI 0.28-3.77, p = 0.98).
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Figure 2 VEGF-C expression in invasive edges of vulvar cancer according to 
the histological Grade.
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Figure 5 Progression-free survival analysis according to VEGF-C expression 
of vulvar tumors (log rank test p=0.19).
Footnote: — negative VEGF-C expression; --- positive VEGF-C expression; + 
censored
VEGF-C expression in SLN metastasis
The SLN metastases were VEGF-C negative in 24% (4/17) 
and VEGF-C positive in 76% (13/17) of the cases (Figure 
3). When the primary tumor was VEGF-C positive, the SLN 
metastasis expressed VEGF-C in 91% (10/11) of the cases 
as compared to 50% (3/6) of the SLN metastases in the 
VEGF-C negative vulvar tumors, but the difference did not 
reach a statistical significance (p = 0.099).
Figure 3 Examples of (a) a weak and (b) a strong VEGF-C immunostaining in 
sentinel lymph node metastases (magnification x 20).
When the SLN metastasis expressed VEGF-C, in 5 cases out 
of 13 (38%) metastatic non-SLNs were also found. However, 
in four cases when the SLN metastasis was VEGF-C negative, 
no other LN metastases were found (0/4; OR 5.82, 95% CI 
0.26-130.89, p = 0.267). The positive predictive value of 
VEGF-C expression in the SLN metastasis in relation to the 
non-SLN metastases was 38 % and the negative predictive 
value 100%, bearing in mind the small number of VEGF-C 
negative SLN metastases.
VEGF-C expression and the clinical course of the disease
In primary tumors: Excluding three patients that died before 
the completion of the primary treatment, the patients with 
VEGF-C positive primary tumors seemed to relapse more 
often (39%, 11/28) during the follow-up than the patients 
with VEGF-C negative tumors (15%, 2/13), although the risk 
was not statistically significant (RR 2.55, 95% CI 0.66-9.90, p 
= 0.18). The VEGF-C positive tumors recurred mostly in the 
vulvar area (64%, 7/11) while the VEGF-C negative tumors 
recurred in the inguinal area (100%, 2/2). The risk of 
groin recurrence was significantly lower, when the tumor 
expressed VEGF-C (RR 0.36, 95% CI 0.16-0.79, p = 0.01).
The disease-specific survival (DSS) as a function of the 
VEGF-C expression of the primary tumors is shown in 
Figure 4. No difference was observed (Log rank test, p = 
0.83). There seemed to be a trend towards a better PFS in 
patients with VEGF-C negative tumors when compared to 
VEGF-C positive tumors, see Figure 5. However, this trend 
did not reach a statistical significance (Log rank test, p = 
0.19).
Figure 4 Disease-specific survival analysis according to VEGF-C expression 
of vulvar tumors (log rank test p=0.83).
Footnote: — negative VEGF-C expression; --- positive VEGF-C expression; + 
censored
In SLN metastases: There was no difference in the risk of 
recurrence between patients with VEGF-C positive and 
negative SLN metastases (5/12 and 1/3, respectively, 
RR 1.25, 95 % CI 0.22-7.08, p = 0.80), respectively. The 
only recurrence in the group with VEGF-C negative SLN 
metastasis appeared in vulvar area whereas three out of 
five recurrences (60%) in the group with VEGF-C positive 
SLN metastasis appeared in inguinal area and two 
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recurrences (40%) in vulvar area. These groups were too 
small for statistical analysis.
Discussion
According to the results of this study, the primary tumors 
of most vulvar cancers express VEGF-C on their invasive 
edges. The frequency of expression tended to correlate 
positively with histological Grade, but the difference 
did not reach statistical significance. VEGF-C was also 
expressed in three quarters of the SLN metastases, more 
often when the primary tumor expressed it, although the 
difference was again not significant. VEGF-C expression 
of the primary tumor was not associated with higher 
surgical Stage or risk of nodal metastasis, nor did it 
have any statistically significant impact on DSS or PFS. A 
negative VEGF-C expression in a SLN metastasis could be a 
favourable indicator of cancer-free non-SLNs.
When considering the rarity of vulvar cancer, our sample 
size of 44 tumors was representative. However, it was still 
not large enough to show statistical significance between 
different groups even when a trend was observed. The 
strengths of this study were a long follow-up time and its 
clinical orientation. Our median follow-up of 39 months 
was long enough for relapses to become evident. We 
chose to keep the IHC scoring simple, bearing in mind its 
potential application to clinical patient care.
Our finding of the frequency of VEGF-C expression in vulvar 
cancer differs from the only other published report by Jach 
et al. In their much smaller population, VEGF-C expression 
was observed only in 10% (1 out of 10) of vulvar squamous 
cell cancer (SCC) cases. The carcinoma specimens they 
used for the IHC analysis were individually selected [16]. 
However, the authors did not specify, which part of the 
tumor these specimens represented nor did they tell 
the histological Grades of vulvar tumors – a feature that 
in our study seemed to effect on the VEGF-C expression. 
When the expression of VEGF-C was studied from 111 
cervical SCC samples by Gombos et al., it was found to 
be heterogeneous within the tumors. The expression was 
significantly higher in the marginal portions of carcinomas 
compared with the central regions [19]. We also focused 
on the invasive edge of vulvar tumors and noticed the 
same phenomenon as Gombos et al. Furthermore; the 
semiquantitative scoring system Jach et al. used to assess 
VEGF-C expression took into account the percentage of 
VEGF-C positive cells. If central parts of the vulvar tumors 
were used for the immunostaining analysis, it might 
have diminished their scores even when the staining was 
strong.
According to literature, SCCs in many different organs 
express VEGF-C, i.e., tumors of oral cavity [20], oesophageal 
cancer [21] and cervical cancer [22]. The positive expression 
has been associated with poorer prognosis and higher risk 
of lymphatic metastasis. However, in our study tumoral 
VEGF-C expression did not predict surgical Stage or 
frequency of the SLN involvement.
We observed that VEGF-C positive cancers tended to recur 
more often than VEGF-C negative cancers, and therefore 
also PFS seemed to be more favorable in patients with 
VEGF-C negative tumors, albeit not significantly. In our 
study population, 43% of patients with a vulvar recurrence 
were successfully salvaged, while all groin recurrences 
were fatal. The risk of groin recurrence was significantly 
lower in VEGF-C positive tumor group than in VEGF-C 
negative tumor group. Better prognosis of the local 
recurrences compared to the groin recurrences might 
partly explain why the positive tumoral VEGF-C expression 
had no impact on the disease-specific survival. The VEGF-C 
expression in SLN metastasis was not associated with the 
recurrence rate.
At the moment, the only known prognostic factor for 
non-SLN metastasis in vulvar cancer in relation to 
characteristics of a SLN metastasis is the size of the 
metastasis. GROINSS-V study showed that the risk for non-
SLN metastasis increases with the size of SLN metastasis. 
No size cut-off existed below which chances of non-SLN 
metastases would be close to zero. Therefore, additional 
treatment was recommended to all SLN positive patients, 
but it always increases side effects and lowers quality of life 
[23]. Our study suggests that a negative VEGF-C expression 
in SLN metastases could act as an indicator of cancer-free 
non-SLNs. However, the small number of metastatic SLN 
samples (four) limits drawing conclusions and this finding 
should be tested in a larger population. If reproducible, 
VEGF-C expression in SLN metastasis could serve as 
another prognostic factor when considering additional 
treatment.
Conclusion
VEGF-C expression was frequent in the invasive edges 
of malignant vulvar tumors and their SLN metastases. If 
verified in a larger population, the lack of VEGF expression 
in SLN metastasis may in the future prove to be a useful 
indicator of lower risk for non-sentinel lymph node 
metastasis. Otherwise, VEGF-C expression in primary 
tumors did not seem to function as a helpful indicator of 
surgical Stage or prognosis in vulvar cancer.
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